MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Study summary

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedVolrustomig and Pemetrexed

Plus 4 other study approaches.

Who it may be forMesothelioma · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 23, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 3

Interventional

Where is it offered?151 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: AstraZeneca
Interventions being studied: Drug: Volrustomig; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Nivolumab; Drug: Ipilimumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Mesothelioma→

Disease setting

Early-stage or resectable→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Key
Participant must be ≥ 18 years at the time of screening
Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)
Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy)
WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS\>1) over the previous 2 weeks prior to day of first dosing
Has measurable disease per modified RECIST1.1
Has adequate bone marrow reserve and organ function at baseline Key

Reasons someone may not be able to joinExclusion criteria

As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results.
Active or prior documented autoimmune or inflammatory disorders
History of another primary malignancy with exceptions.
Uncontrolled intercurrent illness
Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled
Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment
Untreated or progressive CNS metastatic disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteSanta Rosa, California
Research SiteAurora, Colorado
Research SiteJacksonville, Florida
Research SiteAtlanta, Georgia
Research SiteChicago, Illinois
Research SiteRochester, Minnesota
Research SiteSt Louis, Missouri
Research SiteCommack, New York
Research SiteColumbus, Ohio
Research SitePortland, Oregon
Research SitePortland, Oregon
Research SitePhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 23, 2026. Always confirm current availability with the study team.

View original record ↗